873. A Retrospective Cohort Study on Treatment Outcomes of Patients on Third-Line Therapy at the HIV Advanced Treatment Centre, University Teaching Hospital, Zambia

BACKGROUND: In Zambia, third-line regimens consist of a switch to darunavir/ritonavir (DRV/r) and/or raltegravir (RAL) and/or etravirine (ETV), and as of 2017, dolutegravir (DTG), from a failing second-line therapy.(5) We assessed virologic suppression (HIV viral load (VL) ≤1000 copies/ml per Zambia...

Descripción completa

Detalles Bibliográficos
Autores principales: Toeque, Mona-Gekanju, Lindsay, Brianna, Zulu, Paul Msanzya, Fwoloshi, Sombo, Chanda, Duncan, Mupeta, Francis, Siwingwa, Mpanji, Mbewe, Melody, Chirwa, Lameck, Hachaambwa, Lottie, Mulenga, Lloyd, Claassen, Cassidy
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2021
Materias:
Poster Abstracts
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8644397/
http://dx.doi.org/10.1093/ofid/ofab466.1068

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8644397/
http://dx.doi.org/10.1093/ofid/ofab466.1068

Ejemplares similares